Oguzhan Ekrem TURAN, Oktay GÜLCÜ, Emrah AKSAKAL, Kayıhan KARAMAN, Selami DEMİRELLİ, Gökhan CEYHAN, Mustafa ÖZTÜRK, Ali Fuat KORKMAZ

Evaluation of the relationship between coronary slow flow phenomenon and serum magnesium levels

Aim: Coronary slow flow phenomenon (CSFP) is a microvascular circulation disorder. It is known that serum magnesium has positive effects on anti-inflammation, vasodilatation and endothelial functions. This observational study investigated the association of serum magnesium levels with CSFP.Materials and Methods: Patients who had undergone coronary angiography (CAG) after noninvasive testing were included in the study. CAG records were reassessed for CSFP and 100 patients were diagnosed as having CSFP. Control subjects (n = 80) had normal coronary flow. Serum Mg levels and other biochemical parameters such as glucose, creatinine, cholesterol levels and hemoglobin samples were collected before CAG. Serum Mg values were categorized into two groups: Mg levels equal/under and above 1.9 mg/dL.Results: The mean patient age was 56.1±9.7 years; 68.9% of patients were men. Patient’s hypertension, diabetes mellitus history and smoking habits rate were similar between groups. Biochemical tests revealed lower serum magnesium levels (1.87 vs 1.95mg/dL, p=0.02) for CSFP patients and controls, respectively. In multivariate regression analysis, a serum magnesium level under 1.9 mg/dL (OR:3.33, 95% CI:1.75-6.37, p

PDF

___

1. Tambe AA, Demany MA, Zimmerman HA, et al. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J 1972; 84:66-71.
2. Singh S, Kothari SS, Bahl VK. Coronary slow flow phenomenon: an angiographic curiosity. Indian Heart J 2004;56:613-7.
3. Cesar LA, Ramires JA, SerranoJunior CV, et al. Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 1996;29:605-13.
4. Xia S, Deng SB, Wang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels 2011;26:480-6.
5. Larkin SW, Clarke JG, Keogh BE, et al. Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. The American journal of cardiology 1989;64:956-8.
6. Clarke JG, Davies GJ, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987;1:1057-9.
7. Camsarl A, Pekdemir H, Cicek D, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003; 67:1022-8.
8. Pekdemir H, Cicek D, Camsari A, et al. The relationship between plasma endothelin-1, nitric oxide levels, and heart rate variability in patients with coronary slow flow. Ann Noninvasive Electrocardiol 2004;9:24-33.
9. Pekdemir H, Polat G, Cin VG, et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 2004;97:35-41.
10. Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients 2015;7:8199-226.
11. Shechter M. Magnesium and cardiovascular system. Magnes Res 2010;23:60-72.
12. Griendling KK, Rittenhouse SE, Brock TA, et al. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986;261:5901-6.
13. Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys 2007;458:33-9.
14. Nielsen FH. Magnesium deficiency and increased inflammation: current perspectives. J Inflamm Res 2018;11:25-34.
15. Libako P, Nowacki W, Rock E, et al. Phagocyte priming by low magnesium status: input to the enhanced inflammatory and oxidative stres responses. Magnes Res 2010;23:1-4.
16. Dibaba DT, Xun P, He K. Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Eur J Clin Nutr 2014;68:510-6.
17. Altura BM, Altura BT. Magnesium and vascular tone and reactivity. Blood Vessels 1978;15:5-16.
18. Gibson CM, Cannon CP, Daley WL, et al. TIMI framecount: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
19. Oktay V, Arat Ozkan A. Coronaryslowflow. Turk Kardiyol Dern Ars 2016;44:193-5.
20. Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn1996;37:375-81.
21. Beltrame JF, Turner SP, Leslie SL, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol 2004;44:57-62.
22. Kostov K, Halacheva L. Role of Magnesium Deficiency in Promoting Atherosclerosis, Endothelial Dysfunction, and Arterial Stiffening as Risk Factors for Hypertension. Int J MolSci 2018;19.
23. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 2011;13:843-7.
24. Song Y, Li TY, van Dam RM, et al. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J ClinNutr 2007;85(4):1068-74.
25. Cetin M, Kiziltunc E, Elalmis OU, et al. Predictive Value of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Patients with Coronary Slow Flow. Acta Cardiol Sin. 2016;32(3):307-312.
26. Elamragy AA, Abdelhalim AA, Arafa ME, et al. Anxiety and depression relationship with coronary slow flow. PLoS One 2019;14.
27. Sadr-Ameli MA, Saedi S, Saedi T, et al. Coronary slow flow: Benign or ominous? Anatol J Cardiol 2015;15:531-5.